Exagamglogene Autotemcel for Severe Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . Methods We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. Results A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. Conclusions Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationA trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy, S., Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715870 · Cited by 216
Self-citation
Cited by
Items 401–477 of 477
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Marone, R., Lepore, R., Paschoudi, K., Zuin, J., Sinopoli, A., Camus, A., Burgold, T., Bartoszek, E. M., Calabrese, D., Toranelli, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.07.736903
The landscape and trajectory of global CRISPR therapeutics
Şahin, C., Formica, T. M., Silva, A., Pelle, G. D., Davis, M. C., Andersen, D. G., Çavdar, M., Santos, L., Qiu, L., Olsen, A. L., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103011 · Cited by 1
Microneedle-Assisted Cell Delivery and Therapy
Qiao, R., Li, D., Wang, L., Zhao, C., Kong, B., & Wu, J. (2026) · Research · doi:10.34133/research.1382 · Cited by 1
Tiwary, P., Oswal, K., & Varghese, R. (2026) · Sexes · doi:10.3390/sexes7030036
“Within this cohort of 29 recruiters, the mean duration of the vaso-occlusive crisis-free interval was reported to be 22.4 months (range, 14.8 to 45.5), and nearly 96.5% patients ( n = 28) exhibited absence of vaso-occlusive crises as of the data cutoff date [110].”
InfluentialA New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia
Steinberg, M. H., & Rees, D. C. (2026) · American Journal of Hematology · doi:10.1002/ajh.70442
Self-citationPatel, A. P., John, T. D., Gottschalk, S. M., Triplett, B. M., Vita, S. D., Stenger, E. O., Sharma, A., & Sheehan, V. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020768 · Cited by 1
Self-citationSupportive care, prevention, and emerging therapies for acute chest syndrome in sickle cell disease
Rice, R. R., & Willen, S. M. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2702549 · Cited by 1
Joshi, G., Natarajan, N., Dickerson, K. E., & Voit, R. A. (2026) · British Journal of Haematology · doi:10.1111/bjh.70675
Yu, M., Das, P., Zhang, X., & Cheng, X. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70304 · Cited by 1
“Summary of gene therapies to treat sickle cell disease (SCD) [3].”
InfluentialGene editing of hematopoietic stem cells: applications and advances
Li, Q., Wang, H., He, Y., Hong, G., & Bao, G. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04251-w
Clinical outcomes of lentiviral gene therapy for SCD
Booth, C., & Jacobsohn, D. A. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020459
Advanced therapy medicinal products for local treatment using new delivery methods
Zaradzki, M., Soethoff, J. P., Sauer, S., Remes, A. K., Müller, O. J., Wagner, A. H., & Morath, B. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118268
ElGohary, G. M., Alsharif, M., Fakih, R. O. E., Lamine, C. B., Shaheen, M., & Aljurf, M. D. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02982-2
Kelly, C. A., Paul, M. A., Griffin, M., Kang, S., Aziz‐Bose, R., Duhaney, L., Fry, C., Umaretiya, P. J., Karvonen, K. A., Esrick, E. B., et al. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70536
Top Ten Tips Palliative Care Clinicians Should Know About Sickle Cell Disease
Allen, A., Nwogu-Onyemkpa, E., Carroll, C. P., Lanzkron, S., Mishkin, A. D., Soodalter, J. A., Treadwell, M. J., Wilson, S. R., Guyer, D. L., Blinderman, C. D., et al. (2026) · Journal of Palliative Medicine · doi:10.1177/10966218261473333
Paiva, A. E. S., Rabelo, I. S., Bertotto, J., Cunha, C. F. D. S. B., da Rosa, C. C., Bergamo, F. M. D. A., Rossetti, M. F. D. O., Vieira, M. F., Santos, E. B., & Alves, S. M. A. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i8.8660
Singh, K., Michaud, D. S., Parness, T., Mgbeke, O. E., Okodaso, H., Jones, K., Ikolo, B. T., Thomas, S., & Ikolo, F. (2026) · Biomedicines · doi:10.3390/biomedicines14081682
“%) were free from severe VOC for at least 12 consecutive months after infusion, and all evaluable patients remained free from VOC-related hospitalization over the same period, with sustained increases in fetal hemoglobin and total hemoglobin maintained throughout follow-up [9,10].”
Krishnamurti, L., Aiyer, A., & Rayapureddi, K. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2711730
Epigenetic strategies for fetal hemoglobin induction in sickle cell disease
de Souza, M. M., Pavan, A. R., Pastre, V. G. D. F., Gini, A. L. R., Silva, R. D. A., Lanaro, C., de Albuquerque, D. M., Costa, F. F., Scarim, C. B., Hodgkinson, J. T., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119186 · Cited by 1
Chen, H., Kadzioch, N. P., Gapp, M., Yang, H.-H., Ruhle, A., Villamizar, J. M., Fuchs, T., Schmacke, N. A., Hornung, V., Speck, R. F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.741689
Cardiovascular Benefits of Disease Modifying Therapies in Sickle Cell Disease: An Evolving Paradigm
Jalil, A., Rajab, F., Srikaram, P., Mazhar, E., Mujahid, A., Rajab, H., & Amir, S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02573-8
Efficient genome editing in the non-human primate brain using programmable extracellular vesiclesPreprint
Liang, X., Zhou, H., Nizamudeen, Z. A., Kyriakopoulou, E., Evans, A. E., Roudi, S., Estupiñan, H. Y., Rädler, J., Hou, V., Daniel, C. D. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.741964
Gene therapy for sickle cell disease: early lessons, enduring questions
Bertaina, A., & Shyr, D. C. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102979
The current state of cerebral complications of sickle cell disease
Cicka, D., Tiratrakoonseree, T., & Fields, M. E. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.08.001
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Liu, J., He, M., Lu, T., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.006 · Cited by 2
Unlocking the curative potential of gene transfer and editing for hematopoietic disorders
Shiroshita, K., Stolz, A., Malouf, C., Tran, V. L., Li, J., Weiss, M. J., & Naldini, L. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105493 · Cited by 1
Gene therapy: The current trajectory of clinical and commercial translation
Gibson, J. R., & Cottle, R. N. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.08.002
Fifteen challenges for generative AI applications to cell biology
Dupire, L., Khan, A. A., Karaletsos, T., Kelley, S., Lundberg, E. K., Ma, J., Paull, E., Quake, S. R., Rabadán, R., Cassius, R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.07.004 · Cited by 4
On-target and off-target activities of CRISPR therapeutics across scales
Magdy, M., Gibson, J. R., Dhungana, A., Herring‐Nicholas, A., Cottle, R. N., & Josephs, E. A. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.07.015 · Cited by 1
Crimi, A. (2026) · Sustainable development goals series · doi:10.1007/978-3-032-21563-5_1
HIV Status Exclusion in Sickle Cell Gene Therapy
Prior, D., & Krishnamurti, L. (2026) · JAMA · doi:10.1001/jama.2026.15933
Hammoud, M. S., & Hanna, R. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00479
Sickle cell gene therapy: the longer, the stronger
Gupta, A. O. (2026) · Blood · doi:10.1182/blood.2026034779
Duminuco, A., Palumbo, G. A., Avella, E., Cupri, A., Garibaldi, B., Limoli, M. C., Mauro, E., Patti, S., Risata, N., Romano, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176520 · Cited by 1
“CRISPR-Cas9-edited autologous CD34+ cells (exagamglogene autotemcel) are approved for both transfusion-dependent β -thalassemia and severe sickle cell disease, alongside lentiviral β - globin gene-addition products [237,238].”
Chandrasekaran, S., Duraisamy, N., Jagadeesan, M., Palukuri, Y. K., & Selvan, S. T. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103007
Gene therapy for hereditary hematological disorders: From clinical breakthroughs to future horizons
Chen, Z., Wang, W., Wu, Y., Qiang, Y., Cheng, W., & Liu, F. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103075
du Rand, A., Masterson, C., Verdon, D. J., Siow, A., Loef, E. J., Dunbar, P. R., Kingston, R. L., Harris, P. W. R., & Sheppard, H. M. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70172
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
“It entails electroporation of an RNP complex composed of Cas9 and a sgRNA targeting a GATA-1 binding motif within the erythroid-specific enhancer region of the BCL11A gene in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) (10, 11).”
InfluentialMatthew, C. O., Inyang, B. A., Ghansah, V., Nwadike, B. C., Tony-Okpalaobi, O. H., & Anyabuoke, A. K. (2026) · Epidemiology and Health Data Insights · doi:10.63946/ehdi/19206
Advanced therapy medicinal products
Aabling, R. R., Revenfeld, A. L., & Rusan, M. (2026) · Ugeskrift for Læger · doi:10.61409/v12251027
Transfusionsmedizinische Versorgung bei Hämoglobinopathien
Cario, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-71825-4_22
An Integrated Gene Therapy Strategy for γ-Globin Addition and HbF Reactivation in β-Thalassemia
Paschoudi, K., Vasiloudis, N.-I., Papadopoulos, F., Nikolaou, X., Παπαδοπούλου, Α., Sova, P., Yannaki, E., & Psatha, N. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030019
Rahmawati, S., Surahman, S. R. B., Indriani, S. F., Niswah, S., & Nasution, S. F. (2026) · Islamicate Futures Knowledge Ethics and Muslim Societies · doi:10.68051/ifkems.v1i2.46
Akhtar, M. S., & Amin, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-02026-4
“Phase 3 studies demonstrated elimination of severe vaso-occlusive crises for at least 12 months in 97% of evaluable patients with sickle cell disease and transfusion independence in 91% of patients with transfusion-dependent β-thalassemia (Frangoul et al. 2024a, b; Locatelli et al. 2024a, b ).”
Aslam, M. N., Weber, M., Al-Hindawi, A., Park, S., Maddineni, G., & Pillai, A. A. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002293
Bartram, M. P., Cukoski, S., Scherrer, P., & Müller, R.-U. (2026) · Nephrologie aktuell · doi:10.1055/a-2835-9943
Ruschke, S., & Karampinos, D. C. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70509
CRISPR/Cas9-Gentherapie zur Behandlung von Hämoglobinopathien
Oevermann, L. (2026) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-026-02456-1
Hemoglobin: The Ideal Conveyor of Oxygen
Deshpande, S., & Rhoades, R. (2026) · Springer eBooks · doi:10.1007/978-3-032-18934-9_9
Genome Editing for Glycogen Storage Diseases
von Beck, T. A., Wang, R., & Koeberl, D. D. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70249
Advancing Gene Editing for Children with Hemoglobinopathies
Thompson, A. A. (2026) · New England Journal of Medicine · doi:10.1056/nejme2607923
Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
“Clinical studies have reported sustained HbF production, marked reductions in vaso-occlusive crises among patients with SCD, and durable transfusion independence in many treated patients with TDT during currently available follow-up (Frangoul et al., 2024; Locatelli et al., 2024).”
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms
Wieland, J., Jackson, P., Penrod, W., Nadauld, S., & Barrott, J. J. (2026) · Cells · doi:10.3390/cells15181647
“Approved CRISPR-edited cellular therapies have demonstrated that targeted genome modification can produce clinically meaningful benefit in selected indications [2,3].”
Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing
Wang, L., Liu, Y., & Han, H. (2026) · Animal Research and One Health · doi:10.1002/aro2.70094
Gene therapy for rare diseases: technological innovation and clinical translation
ZHANG, Y.-J., & Yuan, H. (2026) · Shengming kexue · doi:10.3724/cbls.2026132
The Bone Marrow's Division of Labor in Cardiovascular Disease
Lanzer, J. D., & Hilgendorf, I. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101679
Verma, N., & Arora, S. (2026) · BioTech · doi:10.3390/biotech15040079 · Cited by 3
Targeted genomic integration and rearrangement using prime assembly
Levesque, S., Kawashima, N., Hwang, G., Zeng, J., Toskov, V., Barry, T., Mannherz, W. P., Homfeldt, L., Becerra, B., Schoonenberg, V. A. C., et al. (2026) · Nature · doi:10.1038/s41586-026-11024-2 · Cited by 7
Somaili, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187185
“…mobilization and collection, specialized manufacturing, myeloablative conditioning, and long-term follow-up, while treatment-related toxicity, fertility concerns, cost, infrastructure requirements, and limited global accessibility remain substantial barriers to widespread implementation [63,64].”
Castro, D. A. W., Perugachi, A. C. M., & Fuel, M. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2729189
The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
Kapoor, U., & Bhatia, M. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.004
Self-citationWen, Z., & Su, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70764 · Cited by 1
“Regulatory and clinical data indicate 7,91,92 that haematopoietic stem cells can be collected, subjected to ex vivo editing, quality control, and reinfusion, and can reconstitute the haematopoietic system after conditioning, thus making them suitable for forming a relatively standardized cell…”
InfluentialKlatt, D., Mucci, A., Liu, B., Peschers, M., Schiroli, G., Schambach, A., Manis, J. P., Armant, M. A., Scadden, D. T., Verhoeyen, E., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.09.001 · Cited by 3
Tagne, A. M., Ajeigbe, O. F., Avalos, H. C., Galvani, F., Masri, S. A., Mireles, C., Gupta, K., & Piomelli, D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105037
RNA therapeutics: current status and future directions
Yang, B., Sedano, M. J., Perez, K. L., Vijayaraghavan, M., Reid, V. A., Yallapu, M. M., Chauhan, S. C., Dhandayuthapani, S., Ramos, E., & Gadad, S. S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-03032-5 · Cited by 1
A review of genetic modification for ex vivo cellular therapies
Dinh, A., Zhang, N., & Stroncek, D. F. (2026) · Transfusion · doi:10.1111/trf.70163
Sickle cell disease-specific barriers to in vivo hematopoietic stem cell gene therapy
Choi, R., & Sheehan, V. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.003
“The pharmacological potential of CRISPR-Cas9: Revolutionizing gene therapy and drug development”
Acharyya, S., Behera, B., Pradhan, R., Debata, J., Patra, P. K., Giri, S., & Kumar, H. K. S. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2740083
Electroporation-Mediated Delivery of CRISPR Technologies for Liver Disease Cell Therapy and Modeling
Cottle, R. N. (2026) · Springer eBooks · doi:10.1007/978-3-319-26779-1_289-1
Human genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation
Guo, C., Arora, U. P., Cheng, X., Xu, W., Cato, L. D., Li, R., Lu, H. Y., Lee, A., Yu, F., Agarwal, G., et al. (2026) · Nature · doi:10.1038/s41586-026-11113-2 · Cited by 11
Personalized drug discovery from rare diseases to cancer
Katanaev, V. L. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00085-y
Evolution of Gene Therapy in Hematology
Loves, R. H., & Kohn, D. B. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.005
Gene therapy for hemoglobinopathies
Gibson, N. M., Patel, J., & Kwiatkowski, J. L. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.014
Current translational perspectives for diagnosis and individualized therapy in rare genetic diseases
Niazi, S. K. (2026) · Communications Medicine · doi:10.1038/s43856-026-01962-3
Vives-Corrons, J. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198848
Metadata
- Authors
- Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., Eckrich, M. J., Imren, S., Bower, L., Simard, C., Zhou, W., Xuan, F., Morrow, P. K., Hobbs, W. E., & Grupp, S. A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; IRCCS, Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.); the Department of Pediatrics, Columbia University Irving Medical Center, New York–Presbyterian–Morgan Stanley Children’s Hospital (M.B.), and the Department of Medicine, Division of Hematology–Oncology, Columbia University (M. Mapara) — both in New York; Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX (L.M., M.J.E.); the Hospital for Sick Children and the University of Toronto, Toronto (D.W.); Ann and Robert H. Lurie Children’s Hospital of Chicago (R.I.L.) and the University of Illinois at Chicago (D.R.) — both in Chicago; Royal London Hospital, Barts Health NHS Trust, London (P.T.); Stanford University, Palo Alto (A.J....
- ORCID
- Frangoul, Haydar
- Locatelli, Franco
- Sharma, Akshay
- Bhatia, Monica
- Mapara, Markus
- Wall, Donna
- Liem, Robert I.
- Telfer, Paul
- Shah, Ami J.
- Cavazzana, Marina
- Corbacioglu, Selim
- Rondelli, Damiano
- Meisel, Roland
- Dedeken, Laurence
- Lobitz, Stephan
- Steinberg, Martin H.
- Walters, Mark C.
- Eckrich, Michael J.
- Imren, Suzan
- Zhou, Weiyu
- Xuan, Fengjuan
- Morrow, Phuong Khanh
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1649-1662
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068280
- Cited by
- 493
- References
- 29
- Citations by year
- 2026: 217 · 2025: 201 · 2024: 74
- FWCI
- 137.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vertex Pharmaceuticals
- CRISPR Therapeutics
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, sickle cell disease, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin reactivation, hematopoietic stem and progenitor cells, vaso-occlusive crisis, myeloablative conditioning, busulfan, autologous cell transplantation, cell therapy safety, pediatric patients
- MeSH terms
- Gene Editing, Adolescent, Adult, Anemia, Sickle Cell, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.